Jean-Yves Blay1, Zsuzsanna Pápai2, Anthony W Tolcher3, Antoine Italiano4, Didier Cupissol5, Antonio López-Pousa6, Sant P Chawla7, Emmanuelle Bompas8, Nada Babovic9, Nicolas Penel10, Nicolas Isambert11, Arthur P Staddon12, Esma Saâda-Bouzid13, Armando Santoro14, Fabio A Franke15, Patrick Cohen16, Solenn Le-Guennec16, George D Demetri17. 1. Centre Léon Bérard, Department of Medicine, French Sarcoma Group, European Organisation for Research and Treatment of Cancer, University Claude Bernard Lyon I, Lyon, France. Electronic address: jean-yves.blay@lyon.unicancer.fr. 2. State Medical Centre, Budapest, Hungary. 3. South Texas Accelerated Research Therapeutics (START), San Antonio, TX, USA. 4. Institut Bergonié, Bordeaux, France. 5. Centre Val d'Aurelle, Montpellier, France. 6. Hospital de la Santa Creu i Sant Pau and Networking Research Center, Barcelona, Spain. 7. St John's Hospital, Santa Monica, CA, USA. 8. Centre René Gauducheau, Nantes, France. 9. Institute for Oncology and Radiology of Serbia, Belgrade, Serbia. 10. Centre Oscar Lambret, Lille, France. 11. Centre Georges François Leclerc, Dijon, France. 12. University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 13. Centre Antoine Lacassagne, Nice, France. 14. Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS, Milan, Italy. 15. CACON-Hospital de Caridade de Ijui, Ijui, Brazil. 16. Sanofi, Vitry-sur-Seine, France. 17. Dana-Farber Cancer Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND:Ombrabulin (AVE8062) disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour activity when combined with cisplatin. In this phase 3 trial, we aimed to assess the efficacy and safety of ombrabulin plus cisplatin compared with placebo plus cisplatin in patients with advanced soft-tissue sarcomas. METHODS: We did this multinational, randomised, double-blind, placebo-controlled phase 3 study at 44 centres in ten countries. Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment withanthracycline and ifosfamide were randomly assigned (1:1) to intravenous infusion of ombrabulin 25 mg/m(2) plus cisplatin 75 mg/m(2) or intravenous infusion of placebo plus cisplatin 75 mg/m(2) every 3 weeks. Patients were allocated to treatment using a permuted blocks randomisation scheme (block size of four) via an interactive voice-response system, and stratified by histological subtype. Patients, medical staff, study investigators, and individuals who handled and analysed the data were masked to treatment assignment. Our primary endpoint was median progression-free survival in the intention-to-treat population. Safety analyses were done on all randomised patients who received at least one dose of study drug. This trial is now closed, and is registered with ClinicalTrials.gov, number NCT00699517. FINDINGS:Between June 13, 2008, and April 26, 2012, we randomly assigned 355 patients toombrabulin plus cisplatin (n=176) or placebo plus cisplatin (n=179). Median duration of follow-up was 27·9 (IQR 20·9-33·2) in the placebo group and 30·5 months (20·7-37·6) in the ombrabulin group. Progression-free survival was slightly, but significantly, improved in the ombrabulin group compared with the placebo group (median 1·54 months [95% CI 1·45-2·69] vs 1·41 [1·38-1·58] months; hazard ratio 0·76 [95% CI 0·59-0·98]; p=0·0302). Grade 3 or 4 adverse events occurred more frequently in individuals in the ombrabulin group than in those in the placebo group and included neutropenia (34 [19%] in the ombrabulin group vs 14 [8%] in the placebo group) and thrombocytopenia (15 [8%] vs six [3%] for placebo). Adverse events leading to death occurred in 18 patients in the ombrabulin group and 10 patients in the placebo group. INTERPRETATION: The combination of ombrabulin and cisplatin significantly improved progression-free survival; however, it did not show a sufficient clinical benefit in patients with advanced soft-tissue sarcomas to support its use as a therapeutic option. Predictive biomarkers are needed for the rational clinical development of tumour vascular-disrupting drugs for soft-tissue sarcomas. FUNDING: Sanofi.
RCT Entities:
BACKGROUND:Ombrabulin (AVE8062) disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour activity when combined with cisplatin. In this phase 3 trial, we aimed to assess the efficacy and safety of ombrabulin plus cisplatin compared with placebo plus cisplatin in patients with advanced soft-tissue sarcomas. METHODS: We did this multinational, randomised, double-blind, placebo-controlled phase 3 study at 44 centres in ten countries. Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment with anthracycline and ifosfamide were randomly assigned (1:1) to intravenous infusion of ombrabulin 25 mg/m(2) plus cisplatin 75 mg/m(2) or intravenous infusion of placebo plus cisplatin 75 mg/m(2) every 3 weeks. Patients were allocated to treatment using a permuted blocks randomisation scheme (block size of four) via an interactive voice-response system, and stratified by histological subtype. Patients, medical staff, study investigators, and individuals who handled and analysed the data were masked to treatment assignment. Our primary endpoint was median progression-free survival in the intention-to-treat population. Safety analyses were done on all randomised patients who received at least one dose of study drug. This trial is now closed, and is registered with ClinicalTrials.gov, number NCT00699517. FINDINGS: Between June 13, 2008, and April 26, 2012, we randomly assigned 355 patients to ombrabulin plus cisplatin (n=176) or placebo plus cisplatin (n=179). Median duration of follow-up was 27·9 (IQR 20·9-33·2) in the placebo group and 30·5 months (20·7-37·6) in the ombrabulin group. Progression-free survival was slightly, but significantly, improved in the ombrabulin group compared with the placebo group (median 1·54 months [95% CI 1·45-2·69] vs 1·41 [1·38-1·58] months; hazard ratio 0·76 [95% CI 0·59-0·98]; p=0·0302). Grade 3 or 4 adverse events occurred more frequently in individuals in the ombrabulin group than in those in the placebo group and included neutropenia (34 [19%] in the ombrabulin group vs 14 [8%] in the placebo group) and thrombocytopenia (15 [8%] vs six [3%] for placebo). Adverse events leading to death occurred in 18 patients in the ombrabulin group and 10 patients in the placebo group. INTERPRETATION: The combination of ombrabulin and cisplatin significantly improved progression-free survival; however, it did not show a sufficient clinical benefit in patients with advanced soft-tissue sarcomas to support its use as a therapeutic option. Predictive biomarkers are needed for the rational clinical development of tumour vascular-disrupting drugs for soft-tissue sarcomas. FUNDING: Sanofi.
Authors: Christine A Herdman; Tracy E Strecker; Rajendra P Tanpure; Zhi Chen; Alex Winters; Jeni Gerberich; Li Liu; Ernest Hamel; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney Journal: Medchemcomm Date: 2016-09-22 Impact factor: 3.597
Authors: Laxman Devkota; Chen-Ming Lin; Tracy E Strecker; Yifan Wang; Justin K Tidmore; Zhi Chen; Rajsekhar Guddneppanavar; Christopher J Jelinek; Ramona Lopez; Li Liu; Ernest Hamel; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney Journal: Bioorg Med Chem Date: 2016-01-06 Impact factor: 3.641
Authors: K Laxmi Swetha; Kavya Sree Maravajjala; Shyh-Dar Li; Manu Smriti Singh; Aniruddha Roy Journal: Drug Deliv Transl Res Date: 2022-06-13 Impact factor: 4.617
Authors: Andres M Arias Lorza; Harshan Ravi; Rohit C Philip; Jean-Philippe Galons; Theodore P Trouard; Nestor A Parra; Daniel D Von Hoff; William L Read; Raoul Tibes; Ronald L Korn; Natarajan Raghunand Journal: Sci Rep Date: 2020-09-02 Impact factor: 4.379